Celcuity (NASDAQ:CELC) is a biotechnology company dedicated to revolutionizing the diagnosis and treatment of cancer and other diseases by developing novel cellular analysis technologies. With a strong focus on identifying new therapeutic candidates and advancing precision medicine, Celcuity concentrates on the development of tests that enable the personalization of treatments to improve patient outcomes. Their projects often involve collaborative efforts with leading pharmaceutical companies, aiming to tailor therapies that are more effective and reduce unnecessary exposure to potentially ineffective drugs. Celcuity's primary objective is to bridge the gap between drug development and clinical diagnostics, ensuring patients receive optimal, targeted therapies based on the unique characteristics of their disease.